Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Huntington disease-like 3 is a rare Huntington disease-like syndrome characterized by childhood-onset progressive neurologic deterioration with pyramidal and extrapyramidal abnormalities, chorea, dystonia, ataxia, gait instability, spasticity, seizures, mutism, and (on brain MRI) progressive frontal cortical atrophy and bilateral caudate atrophy.
Features include: Mutism, Frontal cortical atrophy, Dystonia, and Abnormal speech pattern and 13 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 10 | Mutism, Dystonia, Abnormal speech pattern |
Muscles |
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Huntington disease-like 3.
25 publications have been identified in PubMed for Huntington disease-like 3. Research spans Basic Science / Preclinical (52%), Case Report / Case Series (16%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 13 | 52% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:36 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Huntington disease-like 3
3
Frontal cortical atrophy, Flexion contracture, Shrinkage of the caudate nucleus (brain) (caudate atrophy) |
Kidneys and urinary system | 1 | Urinary incontinence |
4 |
16% |
Disease patterns and progression | 4 | 16% |
Research summaries | 2 | 8% |
Clinical study results | 1 | 4% |
New treatment approaches | 1 | 4% |
Daida T (2026). [PMID: 41720207](https://pubmed.ncbi.nlm.nih.gov/41720207/). *Experimental neurology*. [Basic Science / Preclinical]
Huang L (2026). [PMID: 41139934](https://pubmed.ncbi.nlm.nih.gov/41139934/). *Clinical genetics*. [Basic Science / Preclinical]
Rafeeq M (2026). [PMID: 41832722](https://pubmed.ncbi.nlm.nih.gov/41832722/). *Current neuropharmacology*. [Epidemiology / Natural History]
Taha M (2026). [PMID: 41762337](https://pubmed.ncbi.nlm.nih.gov/41762337/). *Neurochemical research*. [Basic Science / Preclinical]
Antolin-Sanfeliz I (2026). [PMID: 41074680](https://pubmed.ncbi.nlm.nih.gov/41074680/). *Mov Disord Clin Pract*. [Epidemiology / Natural History]
Katariya R (2026). [PMID: 42070762](https://pubmed.ncbi.nlm.nih.gov/42070762/). *Eur J Pharmacol*. [Basic Science / Preclinical]
Kadan J (2026). [PMID: 42172657](https://pubmed.ncbi.nlm.nih.gov/42172657/). *Prim Care Companion CNS Disord*. [Case Report / Case Series]
Alenezi SK (2025). [PMID: 40603982](https://pubmed.ncbi.nlm.nih.gov/40603982/). *Scientific reports*. [Basic Science / Preclinical]
Rocha DL (2025). [PMID: 39969791](https://pubmed.ncbi.nlm.nih.gov/39969791/). *Journal of community genetics*. [Basic Science / Preclinical]
Ramírez-García MÁ (2025). [PMID: 40187026](https://pubmed.ncbi.nlm.nih.gov/40187026/). *Archives of medical research*. [Epidemiology / Natural History]
AI-curated news mentioning Huntington disease-like 3
Updated Sep 2, 2026
The company is now hoping for an affirmative answer on its application after an unusually turbulent year dealing with U.S. regulators.
The biologics license application follows months of public speculation—and regulatory reversals—for uniQure’s AMT-130. If accepted by the FDA for priority review, approval could come in the second quarter of 2027.
A recent case series and systematic review highlights early manifestations and diagnostic pathways in juvenile-onset Huntington disease, with a focus on epilepsy in three patients. This research contributes to understanding the clinical presentation and management of this rare condition.
UniQure is ready to put its Huntington’s disease gene therapy through an advisory committee meeting—even as the broader rare disease space has been put on edge by recent FDA scrutiny of assets by Replimune and Capricor.
Early-stage study marks milestone for regenerative medicine